Immune checkpoint inhibitor-induced myocarditis with myositis and/or myasthenia gravis overlap syndrome: A case series. (PubMed, Exp Ther Med) - Oct 8, 2026 - "Treatments included corticosteroids, intravenous immunoglobulin (IVIG), plasmapheresis and rituximab. Pyridostigmine should be administered with caution in patients with IM3OS, particularly in the presence of bradyarrhythmic ICI-related myocarditis. Given the high mortality and disability rates associated with IM3OS, novel biological targeted therapies such as eculizumab and efgartigimod may reduce fatal outcomes."
Checkpoint inhibition • IO biomarker • Journal • Cardiovascular • CNS Disorders • Fatigue • Gastrointestinal Disorder • Immunology • Inflammation • Musculoskeletal Pain • Myasthenia Gravis • Myositis • Oncology • Pain • TNNI3
|
|
Dantao Peng; Huijuan Cui; Jiabin Zheng; Junyu Ma; Qing Liu; Qing Sun; Renbin Wang; Weihe Zhang; Yanni Lou; Yu Wang
|